Nothing said here yet.
to join the conversation.
| Kulkarni SamarthChief Executive Officer | Sell | 47,837 | $2.4M | Mon, Oct 19 |
| George SimeonDirector | Sell | 14,514 | $720.4K | Wed, Oct 14 |
| Kulkarni SamarthChief Executive Officer | Sell | 4,098 | $201.9K | Wed, Oct 14 |
| KASINGER JAMES R.General Counsel and Secretary | Sell | 1,040 | $51.2K | Wed, Oct 14 |
| KASINGER JAMES R.General Counsel and Secretary | Sell | 1,990 | $119.5K | Tue, Oct 6 |
| KASINGER JAMES R.General Counsel and Secretary | Sell | 10,400 | $626.5K | Tue, Sep 22 |
| Behbahani AliDirector | Sell | 13,679 | $780.9K | Thu, Sep 17 |
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.
CRISPR Therapeutics appointed Andrew J. Silver as Chief Financial Officer and principal financial officer on October 19, 2026, following his tenure as Senior Vice President of Finance and a prior decade in assurance services at Ernst & Young.
CRISPR Therapeutics (NasdaqGM:CRSP) has promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026. Outgoing CFO Raju Prasad, Ph.D., has resigned from his role, also effective October 19, 2026.
The company's gene-editing-focused platform looks promising.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
The valuation of CRSP stock is high, and its pipeline is not advanced.
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.
Agreement gives KU Leuven's Leuven Viral Vector Core access to foundational CRISPR/Cas9 intellectual property, supporting genome editing services for academic and industry researchers worldwide DUBLIN, and LEUVEN, Belgium, Oct.
The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable.